CoChat

Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature

Open access
Zhao, Shangkun, Qiao, Zhi, Pfeifer, Roman, Pape, Hans-Christoph, Mao, Keya, Tang, Hai, Meng, Bin, Chen, Songfeng, Liu, Hongjian · 2024 · European Journal of Medical Research

The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index; 33 of the 40 sources its claims cite were checked for support.

Abstract

The senescence-associated secretory phenotype (SASP) is a generic term for the secretion of cytokines, such as pro-inflammatory factors and proteases. It is a crucial feature of senescent cells. SASP factors induce tissue remodeling and immune cell recruitment. Previous studies have focused on the beneficial role of SASP during embryonic development, wound healing, tissue healing in general, immunoregulation properties, and cancer. However, some recent studies have identified several negative effects of SASP on fracture healing. Senolytics is a drug that selectively eliminates senescent cells. Senolytics can inhibit the function of senescent cells and SASP, which has been found to have positive effects on a variety of aging-related diseases. At the same time, recent data suggest that removing senescent cells may promote fracture healing. Here, we reviewed the latest research progress about SASP and illustrated the inflammatory response and the influence of SASP on fracture healing. This review aims to understand the role of SASP in fracture healing, aiming to provide an important clinical prevention and treatment strategy for fracture. Clinical trials of some senolytics agents are underway and are expected to clarify the effectiveness of their targeted therapy in the clinic in the future. Meanwhile, the adverse effects of this treatment method still need further study.

Overview

CoChat Summary

## TL;DR

This is a narrative review arguing that senescence-associated secretory phenotype (SASP) influences fracture healing, with the literature suggesting that SASP can be both harmful and, in some contexts, potentially reparative. The paper emphasizes that senolytics and other SASP-targeting strategies may help fracture healing, but the mechanisms, dosing, and safety remain uncertain.

## Key findings

  • Public data analyses cited in the review showed that markers of aging and SASP increase during fracture healing, and that fracture healing time is reduced in mice treated with drugs that remove senescent cells.
  • In one fracture-healing tissue study using qRT-PCR, most SASP-related components increased rapidly; CCL7 increased 70-fold at day 14, and Pai1/Serpine1 increased more than 60-fold at day 8 but decreased substantially by day 14.
  • The review reports that IL-6 and TNF-α generally inhibit bone formation and promote osteoclast activity, while TGF-β has context-dependent effects; partial neutralization of TGF-β with antibodies accelerated fracture healing in aged mice.
  • Senolytics such as dasatinib + quercetin were reported to downregulate aging markers in fracture-healing tissue and improve healing in mice, but navitoclax (ABT-263) was also associated with trabecular bone loss and impaired bone formation in aged mice.

## Methods

  • Narrative review of the current literature on SASP, cellular senescence, and fracture healing.
  • Synthesizes prior studies, including public data analyses, qRT-PCR findings in fracture-healing tissues, and animal studies of senolytics and TGF-β neutralization.
  • Main analysis is qualitative integration of published mechanistic and preclinical evidence; no meta-analysis or systematic review method is stated in the text.

## Limitations

  • The paper states that the mechanisms are not yet precise and that further studies are needed to clarify how SASP affects fracture healing and whether SASP-targeted treatment will promote fracture healing.
  • The review explicitly notes that there are relatively few experimental studies on SASP in fracture healing and that the exact composition of SASP remains elusive.
  • Evident from the text: most of the support comes from preclinical and literature-synthesis evidence, with clinical applicability still uncertain; the paper also says the specific dosing method for senolytics “still needs to be simpler” and that adverse effects need further study.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40001-023-01604-7

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 DDR occurs after DNA damage, leading to cellular senescence. Senescent cells have several features: upregulation of the BCL-2 anti-apoptotic protein family (induces resistance to apoptosis, cells undergo oxidative damage (elevated ROS can be detected), metabolic changes (including the presence of SA-β-gal aggregates, SAHF and SASP), cell cycle arrest (p21 and p16 upregulation). Osteoblasts senesce in response to stress stimuli, and these cells likely cause an inflammatory microenvironment in bone by secreting SASP effects that disrupt bone formation and enhance osteoblast function. SASP can promote aggregation of BMSCs, which can differentiate into pre-osteoblasts and osteoblasts. HSCs can differentiate into osteoclasts BMSCs, bone-marrow-derived mesenchymal stem cells. DDR, DNA damage response. RANK, receptor activator of nuclear factor Kappa-B. RANKL, RANK ligand. ROS, reactive oxygen species. SAHF, senescence-associated heterochromatin foci. SASP senescence-associated secretory phenotype, SA-β-gal senescence-associated β-galactosidase. HSC haematopoietic stem cell
Fig. 1 DDR occurs after DNA damage, leading to cellular senescence. Senescent cells have several features: upregulation of the BCL-2 anti-apoptotic protein family (induces resistance to apoptosis, cells undergo oxidative damage (elevated ROS can be detected), metabolic changes (including the presence of SA-β-gal aggregates, SAHF and SASP), cell cycle arrest (p21 and p16 upregulation). Osteoblasts senesce in response to stress stimuli, and these cells likely cause an inflammatory microenvironment in bone by secreting SASP effects that disrupt bone formation and enhance osteoblast function. SASP can promote aggregation of BMSCs, which can differentiate into pre-osteoblasts and osteoblasts. HSCs can differentiate into osteoclasts BMSCs, bone-marrow-derived mesenchymal stem cells. DDR, DNA damage response. RANK, receptor activator of nuclear factor Kappa-B. RANKL, RANK ligand. ROS, reactive oxygen species. SAHF, senescence-associated heterochromatin foci. SASP senescence-associated secretory phenotype, SA-β-gal senescence-associated β-galactosidase. HSC haematopoietic stem cellCC BY · PubMed Central

Verification

Claims the paper makes

27 Valid · 2 Not valid · 5 Not checked · 5 Own results and interpretations

18 more claims · 10 with their cited sources checked

Create a free account to see all 39 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 142 references

Cited by

See all 35

Metadata

Authors
Zhao, S., Qiao, Z., Pfeifer, R., Pape, H.-C., Mao, K., Tang, H., Meng, B., Chen, S., & Liu, H.
Affiliations
  • First Affiliated Hospital of Zhengzhou University (CN)
  • University Hospital Zurich (CH)
  • Chinese PLA General Hospital (CN)
  • Beijing Friendship Hospital (CN)
  • First Affiliated Hospital of Soochow University (CN)
Corresponding author
Liu, Hongjian
Venue
European Journal of Medical Research
Published
2024-01-09
Volume
29
Issue
1
Pages
38-38
ISSN
  • 0949-2321 (ISSN-L)
  • 2047-783X
OpenAlex
W4390744430
Cited by
35
References
143
Citations by year
2026: 16 · 2025: 16 · 2024: 3
FWCI
1.99
Type
journal article
Language
en
Open access
Licence
Locations
  • European journal of medical research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
National Natural Science Foundation of China (82172484)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
senescence-associated secretory phenotype, fracture healing, cellular senescence, senolytics, senolytic therapy, inflammation, inflammatory cytokines, proteolytic enzymes, tissue remodeling, immune cell recruitment, age-related diseases
MeSH terms
Senescence-Associated Secretory Phenotype, Senotherapeutics, Female, Humans, Pregnancy, Cytokines, Fracture Healing, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature. https://app.cochat.ai/papers/10.1186/s40001-023-01604-7
The paper
Zhao, S., Qiao, Z., Pfeifer, R., Pape, H.-C., Mao, K., Tang, H., Meng, B., Chen, S., & Liu, H. (2024). Modulation of fracture healing by senescence-associated secretory phenotype (SASP): a narrative review of the current literature. European Journal of Medical Research. https://doi.org/10.1186/s40001-023-01604-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.